

Cassandra M Berry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7548419/publications.pdf>

Version: 2024-02-01

13
papers

284
citations

933264

10
h-index

1125617

13
g-index

13
all docs

13
docs citations

13
times ranked

654
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies?. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 796-799.	1.4	15
2	A Technique for Inspiring Scientific Inquiry Using a Creative Scenario. <i>American Biology Teacher</i> , 2017, 79, 671-677.	0.1	2
3	Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors. <i>PLoS ONE</i> , 2016, 11, e0158169.	1.1	28
4	Understanding Interferon Subtype Therapy for Viral Infections: Harnessing the Power of the Innate Immune System.. <i>Cytokine and Growth Factor Reviews</i> , 2016, 31, 83-90.	3.2	16
5	Towards a Universal Influenza Virus Vaccine Eliciting Broadly Neutralising Haemagglutinin Antibodies. <i>Journal of Vaccines & Vaccination</i> , 2015, 06, .	0.3	2
6	Modulation of Innate Immune Responses by Influenza-Specific Ovine Polyclonal Antibodies Used for Prophylaxis. <i>PLoS ONE</i> , 2014, 9, e89674.	1.1	11
7	Persistent and Compartmentalised Disruption of Dendritic Cell Subpopulations in the Lung following Influenza A Virus Infection. <i>PLoS ONE</i> , 2014, 9, e111520.	1.1	15
8	Elevated Plasma Soluble CD14 and Skewed CD16+ Monocyte Distribution Persist despite Normalisation of Soluble CD163 and CXCL10 by Effective HIV Therapy: A Changing Paradigm for Routine HIV Laboratory Monitoring?. <i>PLoS ONE</i> , 2014, 9, e115226.	1.1	34
9	Interferon-α, immune activation and immune dysfunction in treated HIV infection. <i>Clinical and Translational Immunology</i> , 2014, 3, e10.	1.7	59
10	Passive Broad-Spectrum Influenza Immunoprophylaxis. <i>Influenza Research and Treatment</i> , 2014, 2014, 1-9.	1.5	4
11	Engineering a Biocompatible Scaffold with Either Micrometre or Nanometre Scale Surface Topography for Promoting Protein Adsorption and Cellular Response. <i>International Journal of Biomaterials</i> , 2013, 2013, 1-16.	1.1	68
12	Interferons as biomarkers and effectors: lessons learned from animal models. <i>Biomarkers in Medicine</i> , 2012, 6, 159-176.	0.6	10
13	Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. <i>Retrovirology</i> , 2011, 8, 75.	0.9	20